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Abstract
Purpose Chemotherapy-induced diarrhoea (CID) is a common, but often underreported problem in patients with breast 
cancer that has a profound effect on quality of life. It is best measured from a patient’s perspective, but tools are limited. 
The aim of this study was to develop and evaluate the Diarrhoea Management Diary (DMD), a self-report measure to assess 
CID, use of self-management strategies and treatment adherence.
Methods The DMD was constructed using an iterative process of instrument development: concept elicitation (literature 
review), item generation and reduction (cognitive debriefing), and pilot testing in the target population. After translation 
into eight languages, the DMD was used in an international randomised trial for women receiving lapatinib and capecitabine 
for metastatic breast cancer with or without prophylactic octreotide. Patterns of missing data and sensitivity to change were 
examined.
Results The understandability and completeness of the 8-item DMD was confirmed in cognitive interviews and pilot testing. 
Practicability of the DMD was evaluated in 62 women with metastatic breast cancer (median age 57). Up to 68% reported 
CID at any given time-point, and 19% had diarrhoea at each time-point. Patients also described efficacy of different strate-
gies for diarrhoea management. Missing data were associated with study discontinuation. DMD missing item response was 
0.9%. Sensitivity to change was good at most assessment points.
Conclusions Although further psychometric testing is recommended, initial evaluation of the DMD showed good content 
validity and practicability in international research with cancer patients.
Keywords Chemotherapy-induced diarrhoea · Adverse effects · Measurement · Patient-reported outcomes · Quality of life · 
Supportive care · Self-management
Introduction
Chemotherapy-induced diarrhoea (CID) is an important and 
commonly observed adverse event (AE) of particular rel-
evance with 5-fluorouracil, irinotecan, capecitabine, anthra-
cyclines, monoclonal antibody or small-molecule therapies 
[1–7]. The prevalence and severity may vary depending 
on chemotherapeutic regimen and dosage, but severe diar-
rhoea has been reported by up to 50% of treated patients 
[1]. It is usually managed symptomatically with antidiar-
rheal agents, diet modification and hydration [2]. However, 
in some patients it may influence their adherence to oral 
medication, lead to treatment delays or dose reduction, all 
of which can reduce the efficacy of treatment [8, 9]. CID 
also interferes with patients’ social and daily activities and 
quality of life (QoL), can increase psychological distress, 
and economic and carer’s burdens [10–13].
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Accurate reporting is crucial for good management of 
CID. The widely adopted Common Terminology Criteria 
for Adverse Events (CTCAE) developed by the US National 
Cancer Institute (NCI), are the current standard for iden-
tification and grading of treatment-related AEs, including 
diarrhoea [14]. Although the CTCAE grading system is uni-
versal and important, it has limitations because it focuses 
primarily on the degree of medical intervention needed, and 
does not take into account patient’s perception of symptoms 
or impact on daily activities and QoL. Furthermore, the 
information is collected from medical records or by clini-
cians. Previous research has highlighted that there is low 
agreement between patients’ and clinicians’ AEs reporting, 
with clinicians frequently underestimating incidence and 
severity [15–17]. There is also poor concordance between 
patient-reported outcomes and clinical trial documenta-
tion, like case report forms or AE logs [18]. The increasing 
number of oral therapies now available for the treatment 
of cancer, raises another concern – that of adherence [19, 
20]. Research suggests that many cancer patients struggle to 
take their medications as prescribed, with adherence often 
declining over time [20]. Medication factors (toxicity, AEs) 
were associated with nonadherence, therefore if CID is not 
managed well, patients may stop taking their medication, 
reducing potential treatment efficacy.
There is growing evidence that patient-reported outcome 
measures (PROs) provide important symptom data and are 
more sensitive in describing symptom burden compared 
to standard toxicity assessment tools. Many clinical tri-
als incorporate PROs, usually generic instruments like the 
EuroQoL 5D-5L [21], or cancer-specific scales, including 
the Functional Assessment of Cancer Therapy-General 
(FACT-G) [22] or the European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire 
[23]. However, these commonly used PROs have little to no 
assessment of diarrhoea, and do not fully capture its impact 
on QoL. A symptom-specific subscale, the Functional 
Assessment of Chronic Illness Therapy for patients with 
Diarrhea (FACIT-D) was developed to be used alongside the 
FACT-G [24]. The FACIT-D contains 11 items to measure 
stool frequency, bowel control, incontinence, sleep disrup-
tion, emotional impact, and limitations of physical, social 
and sexual functioning. It has been used in international 
research, predominantly in trials examining the use of pro-
phylactic drugs or other products in preventing or reducing 
CID [25–30]. Although the subscale measures QoL specific 
to diarrhoea, it lacks evaluation of symptom management, 
such as self-care and management strategies related to diet, 
nutritional supplements, and medication administration. The 
aim of this two-phase study was to design a measure that 
could be used alongside the FACIT-D, or separate from it, 
to monitor the presence and severity of CID and to capture 
some ways in which patients might control this when taking 
anticancer drugs. This paper describes the development and 
initial evaluation of this new tool, the Diarrhoea Manage-
ment Diary (DMD).
Methods
Phase 1: development of the DMD
Phase 1 followed the recommendations from ISPOR’s Good 
Research Practices Task Force Reports [31, 32]. An iterative 
process of instrument development was used that focused on 
questionnaire design and scaling, pilot testing and revision 
of preliminary versions (Fig. 1). To inform the selecting of 
items, a rapid concept-focused literature review [33] was 
conducted exploring information about CID and self-man-
agement strategies, and existing questionnaires of treatment/
disease-related diarrhoea, or bowel dysfunction. Preliminary 
testing was carried out with an initial list of items to refine 
the draft instrument. Cognitive debriefing interviews were 
conducted in cancer patients with gastrointestinal symptoms, 
or bowel conditions (coeliac, inflammatory bowel disease) 
Review of literature and existing PROs
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Selection of key concepts to be assessed
Selection of items 
(10-item version, open/closed questions, 2 formats)
Corrections: 9-item version 
(stool volume item removed)
Cognitive debriefing: n=6, healthy volunteers
Collection normative data on bowel habits 
(DMD items 1-3): n=81, healthy volunteers
Development international 8-item version 
(free-text box removed)
Pre-test in cancer patients on chemotherapy: 
n=9, baseline and 3 weeks of follow-up 
PHASE 2: Preliminary evaluation in metastatic breast cancer 
patients receiving lapatinib and capecitabine
(n=62, 24 week follow-up)
Fig. 1  The process of the development of the Diarrhoea Management 
Diary (DMD)
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and controls who were selected by convenience sampling. 
An interview guide was used to assess instructions, interpre-
tation of content, item relevance/order, word clarity, format 
and length.
Phase 2: evaluation of the DMD
Study design and sample
The objective of phase 2 was to determine whether the 
DMD is easy to understand and appropriate for use in cancer 
patients. Data were collected in an international multicentre 
randomised trial investigating the prophylactic use of long-
acting release octreotide on reducing diarrhoea associated 
with treatment for metastatic breast cancer (NCT02294786). 
Eligible patients were women aged 18 years or older with 
HER2-positive advanced or metastatic breast cancer which 
had progressed following prior therapy. Patients were ran-
domised to receive octreotide (40 mg 7 days before chem-
otherapy and 28 days later) or no octreotide. All patients 
received combination therapy with lapatinib (1250  mg 
once daily continuously) and capecitabine (1000 mg/m2 
twice daily on days 1–14 of a 21-day cycle) until disease 
progression.
Study procedures and measures
Self-reported diarrhoea, information on CID management, 
and treatment adherence was collected at baseline using the 
DMD (items 1–3 only) and on a weekly basis after the start 
of chemotherapy (Online Resource 1). QoL was evaluated 
at baseline and every 3 weeks (after each cycle) using the 
FACIT-D (version 4) [22, 24]. The FACIT-D comprises of 
the FACT-G with four subscales measuring physical, social, 
emotional and functional well-being, and the Diarrhoea Sub-
scale (DS,11 items). There are five response options for each 
item with scores ranging from not at all to very much (scored 
0–4). A total summary score is calculated by adding the sub-
scale scores; total FACIT-D scores range from 0–152, and 
total DS scores range from 0–44. Higher values represent 
better QoL.
Statistical analyses
Only patient-reported data (DMD, FACIT-D) were analysed 
(a trial summary is available elsewhere) [34]. FACIT-D 
(total, DS subscale) scores were calculated for each time-
point (baseline, 3, 6, 9, 12, 15, 18, 21 and 24 weeks) using 
the scoring algorithms provided, and missing data were 
treated according to scoring guidelines. Patterns of miss-
ing data were evaluated for both questionnaires. Demo-
graphic characteristics and PRO data were summarised 
using descriptive statistics: means and standard deviations 
(SD) for quantitative variables, and frequencies and percent-
ages for categorical variables. Our CID definition included 
both increased frequency and altered consistency [35]. Self-
reported diarrhoea on the DMD was defined as an increase 
in reported frequency of bowel movements and/or worsening 
in consistency (dichotomised as ‘hard/firm or quite soft’ to 
‘very soft/loose or watery’) from baseline. The proportion 
of patients reporting diarrhoea (yes/no) was summarised for 
each time-point and the total number of diarrhoea episodes 
for each patient was calculated. A severity score was derived 
by dividing the total number of episodes by the number of 
time-points completed, and patients were divided into two 
categories: low/medium severity (i.e. reporting diarrhoea 
less than half of time on study) and high severity (i.e. report-
ing diarrhoea over half of time on study). Independent t-tests 
were performed to compare low/medium with high severity 
groups for differences in age and treatment duration.
To examine the sensitivity to change of the DMD cap-
ture of self-reported diarrhoea, we looked at the association 
between self-report of diarrhoea or not at each time-point 
(classified as described above) with meaningful change on 
the FACIT DS. We used a distribution-based approach to 
determine meaningful change in FACIT DS scores, with the 
threshold for change set at 0.5 SD change from baseline [36]. 
Patients were categorised as reporting meaningful decline, 
improvement or unchanged/stable at each time-point. Chi-
square analyses (Fisher’s exact) were used to contrast the 
proportion of patients reporting meaningful decline or not in 
QoL (FACIT DS) with those self-reporting diarrhoea or not 
(DMD). All statistical analyses were conducted using IBM 
SPPS Statistics for Windows, Version 25.0 (IBM Corp., 
Armonk, N.Y., USA).
Results
Phase 1: development of the DMD
Literature searches were performed using various search 
terms (e.g. diarrhoea OR diarrhea, bowel movement, stools, 
cancer, chemotherapy, radiotherapy, assessment, ques-
tionnaire, PRO) and databases (e.g. Scopus, MEDLINE, 
Cochrane Library). A manual search within the selected 
papers and existing questionnaires was also conducted. The 
results were summarised and revealed a broad range of top-
ics regarding CID and management strategies, and various 
instruments to assess diarrhoea in various medical condi-
tions, like gastrointestinal diseases, bowel cancer and HIV. 
Figure 1 shows the development of a preliminary frame-
work, which included the construction of a provisional list 
of questionnaire items. The draft DMD contained 10 items 
with open-ended and closed questions relating to stool fre-
quency, consistency and volume (item 1–4); self-care and 
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symptom management, including dietary changes (item 
5–7); treatment adherence (item 8, 9); and, an open response 
option (item 10). Two DMD versions were developed, each 
with a different format. Both versions were used in cogni-
tive debriefing with 7 patients and 5 controls (9/12 female; 
mean age 53.6 years, range 37–65), and were completed in 
counterbalanced order.
Analyses after iterative testing showed that the DMD item 
relevance, content interpretation, word clarity, and format or 
length were generally good. No additional items were sug-
gested, but the item about stool volume was removed, and 
the response scales of two items extended. Other revisions 
consisted of layout changes. The revised DMD was admin-
istered to healthy volunteers (n = 6) for a small-scale field 
pre-test, and no further modifications were implemented.
Data were collected from a convenience sample of 81 
healthy adults (50/81 female; mean age 46.3 years, range 
20–66) to gather information about normative ranges for 
stool frequency and consistency (DMD items 1 to 3). The 
results were in line with published data [37–39] and showed 
that 95% had 1 to 3 bowel movements daily, mostly (93.7%) 
hard/firm or quite soft.
A DMD format with closed-ended questions was con-
structed for use in international research to enable easier 
quantification. The acceptability of this closed-format ver-
sion was tested in a local teaching hospital as part of an 
audit. Nine cancer patients (6/9 female; 7/9 breast or bowel 
cancer; mean age 57.6 years, range 41–66) before the start 
of chemotherapy (items 1–3 only), followed by a weekly 
assessment for 3 consecutive weeks. They showed no prob-
lems of understanding the questions, and there were no miss-
ing values which might be a good indicator of acceptability.
The final version of the DMD has 8 items organised in 
three sections: (i) bowel habits (items 1–3); (ii) self-care and 
diarrhoea management (items 4–6, including 4 sub-items); 
and (iii) treatment adherence (items 7, 8). The DMD has no 
numerical scoring system, but changes over time for cat-
egorical and dichotomous responses can be charted either 
for each individual (showing diarrhoea onset and/or resolu-
tion) or for groups of patients, if used within a clinical trial 
setting. Cross-cultural translations were completed by the 
FACITtrans group for eight languages to use the measure in 
international research.
Phase 2: evaluation of the DMD
Sample characteristics
Between December 2014 and April 2016, 62 patients from 
17 centres in 5 countries were enrolled. Recruitment ended 
in September 2016, and the trial was stopped early due to 
futility (i.e. an interim analysis revealed that prophylac-
tic octreotide did not result in a statistically significant or 
clinically meaningful reduction in occurrence of physician 
reported grade ≥ 2 diarrhoea) [34]. The median age was 
57 years (range 33–81), and mean time since initial diagno-
sis to study entry was 4.3 years. All except one had cancer-
related surgery, and all had prior systemic therapy. Thirty-
seven (59.7%) patients completed 8 cycles of study treatment 
and 24 weeks follow-up. The most frequently recorded rea-
son for study discontinuation was disease progression.
PRO completion
A total of 1220 DMDs (77.3% of the expected number of 
questionnaires) and 470 FACIT-Ds (80.1% of the expected 
number of questionnaires) were completed. Overall comple-
tion rates ranged from 98.4% at baseline to 59.7% at the end 
of study (Online Resource 2). In total, 60 patients (96.8%) 
completed both PROs at baseline and at least one subsequent 
time-point. Completion rates remained high until week 15 
(71.0%). Over half of patients (n = 32; 51.6%) completed all 
PROs from baseline to week 24. Missing data were predomi-
nantly associated with study discontinuation (due to disease 
progression). Only one patient (1.6%) requested to stop the 
PRO completion due to a high burden.
Partial response (the occurrence of missing items) was 
found on 66 DMDs (from 28 patients) and 96 FACIT-Ds 
(from 34 patients), with respectively 85 (0.9%) and 282 
(1.6%) item responses missing. Missing DMD data (main 
items only) were more frequent for questions that assessed 
diarrhoea management and self-care strategies (items 4–6; 
accounting for 55.3% of missing item responses). Missing 
item response on the FACIT-D was often observed on DS 
subscale items (146/282; 51.8%), or items related to sex-
ual activity (81/282; 28.7%), and was treated according to 
the scoring guidelines which allows a subscale score to be 
prorated for missing items if greater than 50% of items are 
answered.
PRO analysis
A total of 58 patients were used for the PRO analysis; 3 
patients were excluded because they had diarrhoea at base-
line (≥ 6 stools daily) and 1 patient lacked post-baseline data. 
Before the first dose of octreotide and start of chemotherapy, 
98.3% of patients had ≤ 2 daily stools and consistency was 
either hard/firm (47%) or quite soft (53%). The presence of 
self-reported diarrhoea after the start of chemotherapy was 
calculated for each patient separately. Table 1 shows bowel 
habits and occurrence of self-reported diarrhoea at follow-
up (ranging from 42% to 67.9%). Eleven patients (19%) had 
persistent diarrhoea (diarrhoea at every time-points), and 6 
(10.3%) reported no diarrhoea symptoms during treatment. 
Patients grouped by diarrhoea severity did not differ signifi-
cantly in age or treatment duration (p > 0.05).
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Table 2 shows the proportions of patients with DMD 
grading of diarrhoea or not and meaningful improvement, 
deterioration or stable scores on the FACIT DS. The major-
ity of patients showed a meaningful decline from baseline at 
each time-point. Because very few patients showed improve-
ment at each time-point, the stable and improvement groups 
were collapsed for further exploratory analyses. Chi-square 
analyses (Fisher’s exact) showed significant associations 
between DMD grading of diarrhoea and meaningful decline 
on the DS at all follow-up time-points with the exception of 
week 9, suggesting that the DMD grading shows promising 
sensitivity to change in diarrhoea related QoL.
Management and self‑care strategies
Table 3 shows the use of management strategies for diar-
rhoea. In total, 24 patients (41%) tried one or more inter-
ventions, with over half (54%; 13/24) using just one strat-
egy. Interventions were predominantly used within the first 
9 weeks of treatment. Dietary change was the most fre-
quently used approach (reported 83 times by 14 patients) 
and was successful (response options ‘a little’ and ‘quite a 
bit’) for most (84%) who tried this. Following a special diet 
(reported 52 times by 14 patients) was successful in 74%.
One in four patients (15/58) used non-prescribed medi-
cation for bowel control. All had used drugs to reduce fre-
quency of bowel movements, which was successful in 73%. 
Using medication to relieve cramping or pain had a higher 
success rate (78%), but was reported less frequently. Medi-
cation to reduce bowel frequency or cramping and pain was 
ineffective in respectively 10% and 21% of cases.
Seven patients (12%) contacted a HCP other than their 
hospital doctor for advice. This was often a general prac-
titioner (8/16) with most receiving advice on diet, fluids 
intake and rest. No advice was provided about skin care or 
use of supplements.
One in eight patients (12%) adjusted or stopped oral 
chemotherapy to control diarrhoea symptoms, most 
Table 1  Bowel movements and self-reported diarrhoea measured on the DMD during chemotherapy (n = 58)
Wk week, DMD Diarrhoea Management Diary
a Numbers at follow-up do not equal 58 due to study attrition and non/incomplete response
b At baseline before starting treatment 98.3% had ≤ 2 daily stools (mean = 1.1, SD = 0.7)
c At baseline before starting treatment consistency was hard/firm in 47% and quite soft in 53%
d Percentage of patients who selected ‘every day’ on DMD item 2 (‘Over the past week how many days were typically like this?
Follow-up in  weeksa Wk1 Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 Wk8 Wk9 Wk10 Wk11 Wk12
n = 55 n = 56 n = 56 n = 56 n = 56 n = 54 n = 51 n = 50 n = 49 n = 44 n = 45 n = 44
Number stools per  dayb
  Median 2 2 1 2 2 2 2 2 2 1 2 2
  Range 0–7 0–5 0- ≥ 8 0–7 0–7 0–7 0–7 0- ≥ 8 0- ≥ 8 0–5 0–7 0–7
Stool  consistencyc (%)
  Hard/firm 9.1 3.6 14.3 5.4 5.4 7.3 9.8 8 6.1 9.1 8.9 9.1
  Quite soft 67.3 60.7 51.8 62.5 62.5 65.5 66.7 56 67.3 77.3 68.9 59.1
  Very soft/loose 12.7 30.7 26.8 30.4 30.4 21.8 19.6 30 20.4 13.6 20 25
  Watery 10.9 5.4 7.1 1.8 1.8 5.5 3.9 6 6.1 0 2.2 6.8
Self-reported diarrhoea (%) 50.9 66.1 58.9 58.9 67.9 59.3 58.8 52 51 47.7 48.9 56.8
Diarrhoea every  dayd (%) 48 50 37.5 33.3 31.6 19.4 50 38.5 48 38.1 36.4 48
Follow-up in  weeksa Wk13 Wk14 Wk15 Wk16 Wk17 Wk18 Wk19 Wk20 Wk21 Wk22 Wk23 Wk24
n = 42 n = 42 n = 42 n = 39 n = 40 n = 40 n = 37 n = 38 n = 37 n = 37 n = 36 n = 35
Number stools per  dayb
  Median 1 1 2 1 1 1 1 1 1 1 2 2
  Range 0–6 0–6 0–6 0–7 0–7 0–7 0–6 0–5 0–6 0–5 0–7 0–7
Stool  consistencyc (%)
  Hard/firm 11.9 11.9 4.8 15.4 25 15 10.8 16.2 18.9 18.9 11.1 8.6
  Quite soft 69 66.7 66.7 64.1 55 62.5 67.6 64.9 56.8 64.9 72.2 65.7
  Very soft/loose 19  21.4 23.8 15.4 17.5 20 18.9 18.9 21.6 10.8 16.7 20
  Watery 0 0 4.8 5.1 2.5 2.5 2.7 0 2.7 5.4 0 5.7
Self-reported diarrhoea (%) 47.6 50 54.8 51.3 47.5 47.5 48.6 42 45.9 45.9 58.3 57.1
Diarrhoea every  dayd (%) 35 33.3 36.4 40 36.8 31.6 44.4 25 23.5 35.3 28.6 36.8
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frequently during the first 12 treatment weeks. Dose reduc-
tions (on most days of the week) were reported 22 times in 
just under half (45.5%) of patients. Seven patients reported 
that they completely stopped treatment; 40% on most days 
of the week.
Discussion
Diarrhoea is a common debilitating AE of anticancer treat-
ment, often affecting QoL and sometimes long-term out-
comes [40, 41]. In cancer clinical trials AEs reporting is 
mandatory to understand treatment toxicities and monitor 
patient safety, but this is usually done by investigators rather 
than patients [42]. This paper described the development and 
initial evaluation of the DMD, a scale that measures symp-
toms and self-care and management strategies of diarrhoea, 
including adherence to treatment. The content was devel-
oped by literature review and direct patient feedback. During 
the cognitive debriefing process, the DMD was easily under-
stood by controls and cancer patients, and relevant to their 
experiences and management of diarrhoea. The final 8-item 
scale was administered to 62 patients receiving lapatinib and 
capecitabine for metastatic breast cancer in an international 
multicentre randomised trial. A change in the frequency and 
stool consistency was observed in the majority of patients, 
with almost one in five patients having CID at all follow-up 
time-points. DMD diarrhoea grading was associated with 
clinically meaningful change on the diarrhoea subscale of 
the FACIT-D, indicating that our scale was robust enough to 
monitor change in individual patients over time.
There is increasing recognition that integration of PROs 
into both research and clinical care is essential for the deliv-
ery of patient-centred care. PROs can provide meaningful 
data about symptoms, treatment tolerance and QoL, and are 
important to clinicians and patients making informed treat-
ment choices. To improve the accuracy of clinician-reported 
AEs and address the growing need for PROs in cancer trials, 
the NCI developed a PRO version of the CTCAE, the PRO-
CTCAE [43]. For each AE assessed, PRO items assess one 
of the following attributes: frequency, severity, interference 
with usual or daily activities, presence/absence, and amount. 
The PRO-CTCAE has good validity and reliability and now 
serves as a companion to the CTCAE using a software plat-
form [44, 45]. Although this approach may improve AE 
reporting in large clinical trials, diarrhoea on PRO-CTCAE 
is only assessed by the frequency of loose or watery stools 
(as opposed to an increase in stools on the CTCAE). Severity 
Table 2  Overview of self-reported diarrhoea, FACIT-D outcomes and meaningful change scores (n = 58)
FACIT-D the Functional Assessment of Chronic Illness Therapy for patients with Diarrhoea, DS FACIT-D Diarrhoea Subscale, Wk week, DMD 
Diarrhoea Management Diary
a Numbers at follow-up do not equal 58 due to study attrition and non/incomplete response
b Self-reported diarrhoea on the DMD was defined as an increase in reported frequency of bowel movements and/or worsening in consistency 
[35] (dichotomised as ‘hard/firm or quite soft’ to ‘very soft/loose or watery’) from baseline. At baseline before starting treatment 98.3% had ≤ 2 
daily stools (mean = 1.1, SD = 0.7) and consistency was hard/firm in 47% and quite soft in 53%
Study time-
points in 
 weeksa
Baseline 
n = 58
Wk 3
n = 56
Wk 6
n = 54
Wk 9
n = 49
Wk 12
n = 44
Wk 15
n = 42
Wk 18
n = 40
Wk 21
n = 37
Wk 24
n = 35
No  diarrhoeab, 
n (%)
58
(100)
23
(41.1)
22
(40.7)
24
(49.0)
19
(43.2)
19
(45.2)
21
(52.5)
20
(54.1)
15
(42.9)
Diarrhoeab,  
n (%)
– 33
(58.9)
32
(59.3)
25
(51.0)
25
(56.8)
23
(54.8)
19
(47.5)
17
(45.9)
20
(57.1)
FACIT-D, 
mean (SD)
115.3
(17.1)
113.7
(19.5)
108.6
(20.4)
111.2
(21.2)
112.2
(21.0)
109.9
(25.5)
113.0
(22.9)
114.8
(22.3)
115.8
(20.0)
   range 77–147 69–151 64–151 57–147 74–148 45–148 58–148 64–148 70–148
DS score, 
mean (SD)
41.5
(3.6)
37.7
(6.8)
36.5
(6.6)
36.4
(7.6)
37.4
(5.6)
36.8
(7.3)
38.7
(5.8)
39.3
(5.4)
38.5
(5.6)
   range 30–44 16–44 18–44 8–44 22–44 16–44 23–44 24–44 24–44
Improvement, 
n (%)
N/A 5
(8.9)
3
(5.4)
2
(4.3)
3
(7.0)
2
(4.8)
3
(7.9)
3
(7.9)
4
(11.8)
Stable,  
n (%)
N/A 18
(32.1)
14
(25.0)
11
(23.4)
15
(34.9)
11
(26.2)
15
(39.5)
14
(36.8)
9
(26.5)
Deterioration, 
n (%)
N/A 33
(58.9)
39
(69.6)
34
(72.3)
25
(58.1)
29
(69.0)
20
(52.6)
21
(55.3)
21
(61.8)
X2 N/A 4.50 5.01 0.49 7.29 7.63 18.03 6.36 5.38
p-value – 0.034 0.025 .484 0.007 0.006  < 0.0001 0.012 0.020
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of symptoms (important to monitor changes over time) and 
interference with daily living are not evaluated, nor are 
impact on QoL, self-care, symptom management or treat-
ment adherence. Inclusion of additional PROs to cover these 
areas is therefore recommended.
It is also well known that early recognition and manage-
ment of diarrhoea is essential to prevent dose reduction or 
treatment discontinuation. However, management of CID 
varies greatly amongst medical providers, and research 
on self-care methods and symptom management, like die-
tary interventions or nutritional education has been lim-
ited [46–49]. A review of assessment and management of 
chemotherapy-related toxicities in patient with common 
types of cancer showed a lack of research papers addressing 
symptom management interventions or self-care strategies 
for diarrhoea [46]. Our study outcomes showed that self-
care methods were primarily reported by patients during the 
first weeks of treatment, and dietary change was the most 
common strategy to control diarrhoea. Almost a quarter of 
patients used an exclusion diet (e.g. avoiding or limiting 
spicy or fatty food, dairy products) or followed a special diet, 
such as the BRAT diet (i.e. banana, rice, apples, toast diet), 
which was successful in the majority of patients who tried 
this. Having the additional information of possible favour-
able effects of certain self-care methods could be useful and 
could inform patient education about CID.
Strengths and limitations
Our study has several strengths: this newly developed instru-
ment includes assessment of frequency and consistency of 
bowel movements and habits, as well as a thorough evalu-
ation of the use of self-care and management strategies for 
diarrhoea symptoms, and permits some measure of adher-
ence to treatment. We used a sequential design for develop-
ment, evaluation and testing patients receiving treatment for 
metastatic breast cancer. Preliminary data from this multi-
centre international trial showed that the DMD has the abil-
ity to monitor symptoms frequently (weekly) over a longer 
period of time, with relatively low nonresponse rates. The 
scale is available in English and was translated into eight 
other languages, permitting use in international oncology 
clinical trials.
Table 3  Diarrhoea management and self-care strategies measured on the DMD (n = 58)
a Numbers at follow-up do not equal 58 due to study attrition and non/incomplete response
b Avoiding certain foods and/or following a special diet
c Use of medication not prescribed by hospital doctor (i.e. drugs to reduce bowel frequency or cramping/pain)
d Other than hospital doctor (e.g. general practitioner, pharmacist)
e Oral chemotherapy (i.e. lapatinib, capecitabine)
Follow-up in  weeksa Wk1
n = 55
Wk2
n = 56
Wk3
n = 56
Wk4
n = 56
Wk5
n = 56
Wk6
n = 54
Wk7
n = 51
Wk8
n = 50
Wk9
n = 49
Wk10
n = 44
Wk11
n = 45
Wk12
n = 44
Dietary  changesb, n (%) 8
(14)
9
(15)
9
(16)
8
(14
6
(11)
7
(13)
5
(10)
3
(6)
5
(10)
1
(2)
2
(4)
2
(5)
Use of non-prescribed  drugsc, n (%) 5
(9)
7
(12)
7
(12)
7
(13)
5
(9)
7
(13)
3
(6)
3
(6)
5
(10)
0 3
(7)
2
(5)
Contact/advice from  HCPsd, n (%) 1
(2)
2
(4)
4
(7)
2
(4)
0 0 0 4
(8)
3
(6)
0 0 0
Reducing  treatmente, n (%) 1
(2)
1
(2)
1
(2)
0 0 1
(2)
0 2
(4)
3
(6)
0 2 (4) 1
(2)
Discontinuing  treatmente, n (%) 1
(2)
1
(2)
1
(2)
0 0 2
(4)
0 2
(4)
3
(6)
0 2
(4)
1
(2)
Follow-up in weeks Wk13
n = 42
Wk14
n = 42
Wk15
n = 42
Wk16
n = 39
Wk17
n = 40
Wk18
n = 40
Wk19
n = 37
Wk20
n = 38
Wk21
n = 37
Wk22
n = 37
Wk23
n = 36
Wk24
n = 35
Dietary  changesb, n (%) 1
(2.5)
1
(2.5)
2
(5)
0 2
(5)
2
(5)
1
(3)
1
(3)
1
(3)
2
(5)
2
(6)
3
(9)
Use of non-prescribed  drugsc, n (%) 3
(7)
2
(5)
2
(5)
1
(2.5)
2
(5)
1
(2.5)
1
(3)
1
(3)
1
(3)
1
(3)
1
(3)
2
(6)
Contact/advice from  HCPsd, n (%) 0 0 0 0 0 0 0 0 0 1
(3)
0 0
Reducing  treatmente, n (%) 1
(2)
1
(2)
0 1
(3)
1
(3)
2
(5)
0 0 0 1
(3)
2
(6)
1
(3)
Discontinuing  treatmente, n (%) 0 0 0 0 0 2
(5)
0 0 0 0 0 0
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The main limitation of this study is that validity data of 
the DMD is restricted to content validity as the final sam-
ple size and response to individual items was small. Also, 
evaluation of the practicability was conducted in a relatively 
small sample of metastatic breast cancer patients only, and 
the results should be interpreted with this in mind. Future 
research needs to demonstrate further validity and reliability, 
and ascertain whether the scale can be used in more diverse 
cancer populations, including patients receiving non-oral 
anticancer therapies, such as parenteral chemotherapy, some 
types of immunotherapy and radiotherapy.
We should also mention here that after initiation of our 
study another PRO for CID was developed: the Systemic 
Therapy Induced Diarrhoea Assessment Tool [50]. This 
scale assesses onset and duration of diarrhoea, including 
diarrhoea-associated symptoms (e.g. abdominal discomfort, 
urgency), and evaluates impact on QoL (activities of daily 
living, energy levels, mood, social/family life). However, 
measurement of management strategies is limited to use of 
antidiarrhoeal medication, and items addressing treatment 
adherence are lacking.
Conclusion
The DMD is a brief measure developed by means of quali-
tative and quantitative research, including patient feedback 
on several versions of the tool. The DMD was designed to 
measure diarrhoea, and self-care and management strategies 
in adults receiving anticancer treatment. Although further 
psychometric testing in other populations is recommended, 
outcomes reported here provide preliminary evidence of 
promising discriminative ability.
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